- Seagen Inc. sells three novel cancer agents—known as antibody drug conjugates, or ADCs—that work like a guided missile attacking tumors with toxins.
- Pfizer Inc. and Merck & Co. have had early-stage discussions about buying Seagen.
- Seagen has more than nine studies evaluating its ADCs with immunotherapies under way.
- The FDA is reviewing a regimen combining Padcev, an ADC from Seagen and Astellas Pharma Inc., with Merck's Keytruda immunotherapy for treatment of advanced bladder cancer.
- Seagen is also developing next-generation conjugates, including one that showed promise against lung tumors in an early-stage study.
Seagen’s Cancer Therapy Is Making It a Takeover Target
Novel cancer agents could shore up aging pharmaceutical portfolios for big drugmakers
Jared S. Hopkins
/cloudfront-us-east-2.images.arcpublishing.com/reuters/RCWZE2OK3BNCJNRVFOS74NYF7M.jpg)
